{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:14:01Z","timestamp":1788984841294,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01842-7","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:28:44Z","timestamp":1785432524000},"page":"4565-4574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark G.","family":"Lebwohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranga","family":"Gogineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Blachley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Beeghly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"4","key":"1842_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 2","key":"1842_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3899\/jrheum.2023-0511","volume":"50","author":"R Aguero","year":"2023","unstructured":"Aguero R, Woodbury MJ, Lee K, et al. Interleukin (IL)-17 versus IL-23 inhibitors: which is better to treat patients with moderate-to-severe psoriasis and mild psoriatic arthritis in dermatology clinics? J Rheumatol. 2023;50(suppl 2):11\u20133.","journal-title":"J Rheumatol"},{"issue":"3","key":"1842_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"key":"1842_CR4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/jdv.20739","volume":"39","author":"LM Aval","year":"2025","unstructured":"Aval LM, Yiu ZZN, Alabas OA, et al. Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British Association of Dermatologists Biologics and Immunomodulators Register cohort study. J Eur Acad Dermatol Venereol. 2025;39:1785\u201395.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1842_CR5","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/jdv.15653","volume":"33","author":"JJ Crowley","year":"2019","unstructured":"Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1842_CR6","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s13555-022-00800-3","volume":"12","author":"G Becher","year":"2022","unstructured":"Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate to severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343\u201354.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1842_CR7","first-page":"1","volume":"238","author":"KA Drerup","year":"2021","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2021;238(4):1\u20135.","journal-title":"Dermatology"},{"issue":"6","key":"1842_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/dth.12267","volume":"28","author":"F Kerdel","year":"2015","unstructured":"Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28(6):390\u2013403.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1842_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1842_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/jdv.16187","volume":"34","author":"Y Poulin","year":"2020","unstructured":"Poulin Y, Ramon M, Rosoph L, et al. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase\u00a02b and 2 phase\u00a03 trials in patients with moderate-to-severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020;34(7):1500\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1842_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","volume":"160","author":"G Hjort","year":"2024","unstructured":"Hjort G, Schwarz CW, Skov L, Loft N. Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis. JAMA Dermatol. 2024;160(8):830\u20137.","journal-title":"JAMA Dermatol"},{"key":"1842_CR12","doi-asserted-by":"crossref","unstructured":"Calderola G, De Luca E, Balato A, et al. Intraclass switching of IL-23 inhibitors in psoriasis: effectiveness, patterns, and predictors of response\u2014a retrospective multicenter study in Italy. Clin Exp Dermatol. 2026;51(3):451\u20136.","DOI":"10.1093\/ced\/llaf476"},{"key":"1842_CR13","doi-asserted-by":"crossref","unstructured":"Bagel J, Gogineni R, Shaikh A, et al. Real-world tildrakizumab effectiveness and drug survival: a cohort study in the PPD CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2026.","DOI":"10.1007\/s13555-026-01843-6"},{"issue":"9","key":"1842_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/1346-8138.13860","volume":"44","author":"H Honda","year":"2017","unstructured":"Honda H, Umezawa Y, Kikuchi S, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44(9):1015\u20139.","journal-title":"J Dermatol"},{"issue":"10","key":"1842_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamadermatol.2025.2714","volume":"161","author":"M Zhang","year":"2025","unstructured":"Zhang M, Hong S, Wang Q, et al. Biopharmaceutical switching in psoriasis treatment: a systematic review and meta-analysis. JAMA Dermatol. 2025;161(10):1029\u201338.","journal-title":"JAMA Dermatol"},{"key":"1842_CR16","unstructured":"Bates H, Leaf S, Younts J. The medical versus the pharmacy benefit: an overview. Berkeley Research Group, LLC. 2025. https:\/\/www.thinkbrg.com\/insights\/publications\/the-medical-versus-the-pharmacy-benefit-an-overview\/. Accessed 4 Nov, 2025"},{"issue":"24","key":"1842_CR17","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.3390\/jcm12247503","volume":"12","author":"S Giordano","year":"2023","unstructured":"Giordano S, Dapavo P, Ortoncelli M, et al. Interclass switch between IL-17 and IL-23 inhibitors in psoriasis: a real-life, long-term, single-center experience. J Clin Med. 2023;12(24):7503.","journal-title":"J Clin Med"},{"issue":"1","key":"1842_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14584","volume":"34","author":"C Bonifati","year":"2021","unstructured":"Bonifati C, Morrone A, Cristaudo A, Graceffa D. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens: a real-life experience. Dermatol Ther. 2021;34(1):e14584.","journal-title":"Dermatol Ther"},{"key":"1842_CR19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2147\/CCID.S464326","volume":"17","author":"M Megna","year":"2024","unstructured":"Megna M, Ruggiero A, Tommasino N, et al. Effectiveness and safety of tildrakizumab in psoriasis patients who failed anti-IL17 treatment: a 28-week real-life study. Clin Cosmet Investig Dermatol. 2024;17:1037\u201342.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"1842_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/ijd.17005","volume":"63","author":"R Viola","year":"2024","unstructured":"Viola R, Mastorino L, Megna M, et al. Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort. Int J Dermatol. 2024;63(3):351\u20138.","journal-title":"Int J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01842-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01842-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01842-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:13Z","timestamp":1788981673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01842-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1842"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01842-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mark G Lebwohl is an employee of Mount Sinai and receives research funds from: AbbVie, Arcutis Inc., Avotres Therapeutics, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall; AltruBio Inc.; Apogee; Arcutis, Inc.; AstraZeneca; Atomwise; Avotres Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Castle Biosciences; Celltrion; PPD\u2122 CorEvitas\u2122 Clinical Registries, Thermo Fisher Scientific; Dermavant Sciences; Dermsquared; Evommune, Inc.; Facilitation of International Dermatology Education; Forte Biosciences; Galderma; Genentech; Incyte; LEO Pharma; Meiji Seika Pharma; Mindera; Pfizer; Sanofi-Regeneron; Seanergy; Strata; Takeda; Trevi; and Verrica. Mark G Lebwohl is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Mark G Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Ranga Gogineni and Asif Shaikh are employees of Sun Pharmaceutical Industries, Inc. Taylor Blachley, Thomas Eckmann, and Alicia Beeghly are employees and shareholders of Thermo Fisher Scientific. Jerry Bagel has received research funds for the Psoriasis Treatment Center from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Corrona LLC, Dermavant Sciences, Dermira, Lilly, Glenmark Pharmaceuticals Ltd, Janssen, Kadmon Corporation, LEO Pharma, Lycera Corp, Menlo Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, Taro Pharmaceutical Industries Ltd, and UCB; is or has been a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Lilly, Janssen, Novartis, Sun Pharma, and UCB; and is or has been a speaker for AbbVie, Celgene Corporation, Eli Lilly, Janssen, and Novartis.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central institutional review board (IRB, Advarra, protocol number Pro00051221). For academic investigative sites that did not receive a waiver to use the central IRB, approval was garnered from the respective governing IRBs and documentation of approval was submitted to the Sponsor prior to initiating any study procedures. All Registry participants provided written informed consent for participation and publication.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}